Case Report: FGFR1 mutation and massive chromosome loss drive malignant transformation of low-grade gliomas

Ruze Tang1, Yanming Chen2, Dong Wan3,4

  • 1Department of General Surgery, Children's Hospital of Soochow University, Suzhou, China.

Frontiers in Oncology
|December 1, 2025
PubMed

Insights

Mitogen-activated protein kinase (MAPK) pathway alterations drive benign brain tumors. Massive chromosome loss, alongside MAPK pathway gene mutations like FGFR1, may explain rare malignant transformation in these tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The mitogen-activated protein kinase (MAPK) signaling pathway is vital for cell functions and frequently altered in tumors.
  • Mutations in MAPK pathway genes (e.g., BRAF, FGFR, NF1) are observed in brain tumors, often leading to benign neoplasms.
  • Mechanisms underlying the rare malignant progression of MAPK-activated benign brain tumors remain unclear.